Publikace
- Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme2020 | Farmaceutická fakulta v Hradci Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Farmaceutická fakulta v Hradci Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Farmaceutická fakulta v Hradci Králové
- Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism2021 | Farmaceutická fakulta v Hradci Králové
- Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors2020 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?2020 | Farmaceutická fakulta v Hradci Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Farmaceutická fakulta v Hradci Králové
- Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters2019 | Farmaceutická fakulta v Hradci Králové
- Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C32019 | Farmaceutická fakulta v Hradci Králové
Loading network view...